Bottom line
Is TOKE a good fund? The bottom line
TOKE is an actively managed other ETF from Cambria.
Its expense ratio is 0.44% — about $44 a year on every $10,000 invested, cheaper than 76% of other funds we track.
It returned −7.4% over one year, −16.2% a year over five years (as of Dec 31, 2024, per its prospectus).
What stands out
- Low cost: cheaper than 76% of other peers
What to watch
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What TOKE invests in
The Fund seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry.
The Fund is an actively managed exchange -traded fund (ETF) that seeks to achieve its investment objective by investing, under normal market conditions, primarily in (1) Cannabis Companies (defined below), and (2) total return swaps intended to provide exposure to Cannabis Companies. Global equity securities that provide broad exposure to the cannabis industry include companies that (i) engage in or support the legal production, cultivation, and/or sale of cannabis, including marijuana and hemp, such as certain agrobusiness, biotechnology, life sciences, pharmaceutical, retail, finance, and real estate companies, (ii) perform lawful research as to the medical and pharmaceutical applications of marijuana and cannabis extracts, including cannabinoids, or (iii) produce and develop devices, goods, and equipment related to the cannabis industry, including hemp and its legal derivatives…
From the fund's prospectus (filed Aug 28, 2025).
TOKE performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| TOKE | −7.4% | −16.2% | — |
| Other median | +9.2% | +4.9% | +5.3% |
Source: Fund prospectus, as of Dec 31, 2024
What TOKE costs
On a $10,000 investment, TOKE's 0.44% expense ratio costs about $44 a year. The prospectus estimates $746 in total costs over 10 years (assuming 5% annual returns). The median other fund charges 0.95%.